

BIBLIOGRAPHY

- Agbabiaka TB, Savovic J, Ernst E. Methods for causality assessment of adverse drug reactions: A systematic review. *Drug Saf.* 2008;31:21–37. [PubMed: 18095744]
- Akil, HAM. 2006. *Buku Ajar Ilmu Penyakit Dalam*. Edisi IV. Jakarta : Fakultas Kedokteran Universitas Indonesia.
- Allredge, Brian K., et al., 2013. *Koda-Kimble & Young's Applied Therapeutics, The Clinical Use of Drugs*, 10th Edition. Wolters Kluwer. Philadelphia, United States. 669-681.
- Ambulatory Care Visits to Physician Offices, Hospital Outpatient Departments, and Emergency Departments: UnitedStates, 1997. Data from the National Health Care Survey. Hyattsville, MD: National Center for Health Statistics; 1997.
- Antman EM, Bennett JS, Daugherty A, Furberg C, Roberts H, Taubert KA; American Heart Association. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. *Circulation.* 2007;115(12):1634–1642.
- Arakawa T, Fujiwara Y, Sollano J, Zhu Q, Kachintorn U, Rani A, Hahm KB, Takahashi S, Joh T, Kinoshita Y, Matsumoto T, Naito Y, Takeuchi K, Yamagami H, Agustanti N, Xiong H, Chen X, Jang E, Furuta K, Terano A. A 2007 Questionnaire-based Survey of Prescription of Non- steroidal Anti-inflammatory Drugs by Physicians in East Asian Countries. *American Journal of Gastroenterology* 2009; 104:S40–S60.
- Arimone Y, Begaud B, Miremont-Salame G, Fourrier-Reglat A, Moore N, Molimard M, et al. Agreement of expert judgment in causality assessment of adverse drug reactions. *Eur J Clin Pharmacol.* 2005;61:169– 73. [PubMed: 15827761]
- Bashinskaya B. et al. 2011. “Trends in Peptic Ulcer Disease and the Identification of *Helicobacter Pylori* as a Causative Organism: Population-based Estimates from the US Nationwide Inpatient Sample.” *Journal of Global Infectious Diseases.* 3(4):366–370.
- Brunner, L. And Suddarth, D. 2002, *Buku Ajar Keperawatan Medical Bedah*, Edisi 8, EGC, Jakarta, Indonesia.
- Campbell WB, Gomez-Sanchez CE, Adams BV, Schmitz JM, Itskovitz HD. Attenuation of angiotensin II- and III-induced aldosterone release by prostaglandin synthesis inhibitors. *J Clin Invest.* 1979;64(6):1552–1557
- Capone ML, Tacconelli S, Rodriguez LG, Patrignani P. NSAIDs and cardiovascular disease: transducing human pharmacology results into clinical read-outs in the general population. *Pharmacol Rep.* 2010;62(3):530–535.

- Cryer B, Li C, Simon LS, Singh G, Stillman MJ, Berger MF. GI-REASONS: a novel 6-month, prospective, randomized, open-label, blinded endpoint (PROBE) trial. *Am J Gastroenterol*. 2013;108(3):392–400.
- Dahlan, M. Sopiudin. 2013. Besar Sampel dan Cara Pengambilan Sampel dalam Penelitian Kedokteran dan Kesehatan. Salemba Medika. Jakarta.
- Del Valle J. Peptic ulcer disease and related disorders. In: Fauci AS, Kasper DL, ongong DL, and et al, eds. *Harrison's Principles of Internal Medicine 17th Edition*, New York: McGraw-Hill Professional, 2008; 1855–1872.
- Depkes RI. Profil Kesehatan Indonesia. Jakarta: Departemen Kesehatan Republik Indonesia; 2008.
- DeRuiter J, “Non-steroidal anti-inflammatory drugs (NSAIDS),” *Principles of Drug Action*, vol.2, pp.1–25, 2002.
- Ditto AM. Drug allergy. In: Grammer LC, Greenberger PA, editors. *Patterson's Allergic Diseases*. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2002. p. 295.
- Djojodiningrat D. Dispepsia fungsional. In: Sudoyo AW, Setyohadi B, Alwi I, Simadibrata M, Setiati S, editors. *Buku ajar ilmu penyakit dalam*. Edisi ke-4. Jakarta: Pusat Penerbitan Departemen Ilmu Penyakit Dalam Fakultas Kedokteran Universitas Indonesia; 2006
- Dufton, J., 2012. *The Pathophysiology and Pharmaceutical treatment of Gastric Ulcer*. Pharmcon Inc.
- Ferraz JG, McKnight W, Sharkey KA & Wallace JL. Impaired vasodilatory responses in the gastric microcirculation of cirrhotic rats. *Gastroenterology* 1995; 108: 1183-1191.
- Fries J. Toward an understanding of NSAID-related adverse events: the contribution of longitudinal data. *Scand J Rheumatol Suppl*. 1996;102:3–8.
- García Rodríguez LA, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. *Lancet*. 1994;343(8900):769–772.
- Gharaibeh, M.N., Greenberg, H.E., and Waldman, S.A, 1998, Adverse drug reactions: a review, *Drug Information Journal*, 32, 323-338
- Goldstein JL, Lefkowitz JB. Public misunderstanding of nonsteroidal antiinflammatory drug (NSAID)-mediated gastrointestinal (GI) toxicity: a serious potential health threat. *Gastroenterology*. 1998;114:A136
- Grace, R. F., Lin, Y., Edwards, S. R., Power, I., and Mather, L. E., “Effects of diclofenac in the rat tail ischaemia-reperfusion injury model of acute hyperalgesia, ”*Pain*, vol.89, no.2-3, pp.117–125, 2001.

- Hahn, D.W., Carraher, R., and McGuire, J.L., "Effects of suprofen and other prostaglandin synthetase inhibitors in a new animal model for myometrial hyperactivity, "Prostaglandins, vol.23, no. 1, pp.1–16, 1982.
- Harirforoosh S, Asghar W, Jamali F. Adverse effects of nonsteroidal antiinflammatory drugs: an update of gastrointestinal, cardiovascular and renal complications. *J Pharm Pharm Sci.* 2013;16(5):821–847.
- Huang et al. 2002. Role of *H. pylori* infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: A meta-analysis. *Lancet.* 359:14–22.
- Iwakiri, R. dan Fujimoto, K., 2008. Roles of NSAIDs and aspirin in bleeding peptic ulcers. *Clinical Journal of Gastroenterology*, **1**: 33–39.
- Kato I. et al. 1992. "A Prospective Study of Gastric and Duodenal Ulcer and Its Relation to Smoking, Alcohol, and Diet." *American Journal of Epidemiology.* 135(5):521–530.
- Kementerian Kesehatan. 2011. Pedoman Interpretasi Data Klinik. Kementerian Kesehatan Republik Indonesia.
- Laine L, Bombardier C, Hawkey CJ, et al. Stratifying the risk of NSAID-related upper gastrointestinal clinical events: results of a double-blind outcomes study in patients with rheumatoid arthritis. *Gastroenterology.* 2002;123(4):1006–1012.
- Lanza FL. A review of gastric ulcer and gastroduodenal injury in normal volunteers receiving aspirin and other nonsteroidal anti-inflammatory drugs. *Scandinavian Journal of Gastroenterology* 1989.
- Lanza F.L. et al. 2009. Practice Parameters Committee of the American College of Gastroenterology: "Guidelines for prevention of NSAID-related ulcer complications." *American Journal of Gastroenterology.* 104(3):728–38.
- Leape LL. 1995. Preventing adverse drug events. *Am J Health Syst Pharm* 52: 379–382
- Longo, Dan L., Fauci, Anthony S., 2010. Harrison's Gastroenterology and Hepatology. McGraw Hill. New York. United States. 125.
- Macedo AF, Marques FB, Ribeiro CF, Teixeira F. Causality assessment of adverse drug reactions: Comparison of the results obtained from published decisional algorithms and from the evaluations of an expert panel. *Pharmacoepidemiol Drug Saf.* 2005;14:885–90. [PubMed: 16059869]
- Malfertheiner P. et al. 2009. "Peptic Ulcer Disease." *Lancet.* 374:1449–61.
- Martin D.F. et al. 2008. "Campylobacter pylori, NSAIDS, and Smoking: Risk Factors for Peptic Ulcer Disease." *American Journal of Gastroenterology.* 84(10):1268–72.
- Marshall B.J. and J.R. Warren. 1984. "Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration." *Lancet.*, 1:1311–5.

- Matsui H, Shimokawa O, Kaneko T, Nagano Y, Rai K, Hyodo I. The pathophysiology of non-steroidal anti-inflammatory drug (NSAID)-induced mucosal injuries in stomach and small intestine. *J Clin Biochem Nutr* 2011; 48: 107-111 [PMID: 21373261 DOI: 10.3164/jcbs.10-79]
- Medicines: Safety of medicines — adverse drug reactions definition. Fact sheet No. 273. Updated October 2008 WHO. [Last accessed on 2013 Jan 28]. Available from: www.who.int/mediacentre/factsheets/fs293.
- Mégraud.F., 2005. A humble bacterium sweeps this year's Nobel Prize. *Cell*. 123:975–6.
- Miwa H, Ghoshal UC, Fock KM. Asian consensus report on functional dyspepsia. *J Gastroenterol Hepatol* 2012;27:626-41.
- Moore, R.A. Derry, S. Simon, L.S. Emery, P. 2013, Review Article Nonsteroidal Anti-inflammatory Drugs, Gastroprotection, and Benefit Risk. *Wiley Periodicals*. 2014; 14 (4): 378-395.
- Muller, N., Payan, E., Lapique, F., Bannwarth, B., and Netter, P. “Pharmacological aspects of chiral nonsteroidal anti-inflammatory drugs,” *Fundamental and Clinical Pharmacology*, vol.4, no.6, pp.617–634,1990.
- Musa SA, Brecker SJ, Rahman TM, Kang JY. Upper gastrointestinal haemorrhage in the acute cardiac care setting: antiplatelets and endoscopy. *Scott Med J* 2012; 57: 88-91 [PMID: 22555229 DOI: 10.1258/smj.2012.012006]
- Naranjo CA, Busto U, Sellars EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. *Clin Pharmacol Ther*. 1981;30:239–45. [PubMed: 7249508]
- Perkumpulan Gastroenterologi Indonesia. Konsensus Nasional: Penatalaksanaan Dispepsia dan infeksi *Helicobacter pylori* 2014.
- Public Health Advisory – FDA Announces Important Changes and Additional Warnings for COX-2 Selective and Non-Selective Non-Steroidal AntiInflammatory Drugs (NSAIDs) [webpage on the Internet]. Silver Spring, MD: US Food and Drug Administration; 2005 [updated August 16, 2013; accessed October 10, 2014]. Available from: [http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformation for Patients and Providers/ucm150314.htm](http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm150314.htm). Accessed October 10, 2014.
- Rainsford KD & Willis C. Relationship of gastric mucosal damage induced in pigs by anti-inflammatory drugs to their effects on prostaglandin production. *Digestive Diseases and Sciences* 1982; 27: 624-635.
- Rainsford KD, Veto GP. 1987. Side-effects of anti-Inflammatory drugs: Clinical and Epidemiological Agents
- Rainsford KD, Veto GP. 3rd ed. Kluwer Academic Publishers; 1992. Side-effects of anti-inflammatory drugs.

- Rainsford KD. Profile and mechanisms of gastrointestinal and other side-effects from NSAIDs. *Am J Med.* 1999;107:27–36. [[PubMed](#)]
- Robert A, Schultz JR, Nezamis JE & Lancaster C. Gastric antisecretory and antiulcer properties of PGE₂, 15-methyl PGE₂, and 16,16-dimethyl PGE₂. *Gastroenterology* 1976.
- Salena, B.J., Han, R.H., 2013. First Principal of Gastroenterology-The Basis of Disease and an Approach to Management. Janssen-Ortho.
- Salih B. et al. 2007. “*H. pylori* infection and other risk factors associated with peptic ulcers in Turkish patients: A retrospective study.” *World Journal of Gastroenterology*. 13(23):3245–8.
- Schiffmann R. et al. 1998. “Constitutive achlorhydria in mucopolidosis type IV.” *Proceeds of the National Academy of Science – U.S.A.* 95(3):1207–12.
- Shah AA, Thjodleifsson B, Murray FE, Kay E, Barry M, Sigthorsson G, et al. Selective inhibition of Cox-2 in humans is associated with less gastrointestinal injury: A comparison of nimesulide and naproxen. *Gut.* 2001;48:339–46. [[PMC free article](#)] [[PubMed](#)]
- Simon RA, Namazy J. Adverse reactions to aspirin and nonsteroidal antiinflammatory drugs (NSAIDs) *Clin Rev Allergy Immunol.* 2003;24:239–52. [[PubMed](#)]
- Singh G. Gastrointestinal complications of prescription and over-the-counter nonsteroidal anti-inflammatory drugs: a view from the ARAMIS database. Arthritis, Rheumatism, and Aging Medical Information System. *Am J Ther.* 2000;7(2):115–121.
- Solomon, Daniel H. 2015. Patient Information : Nonsteroidal Anti-inflammatory Drugs (NSAIDs). Wolters Kluwer
- Srinivasan R, Ramya G. Adverse drug reaction — Causality assessment. *Int J Res Pharm Chem.* 2011;1:606–12.
- Sturkenboom M, Nicolosi A, Cantarutti L, Mannino S, Picelli G, Scamarcia A, et al. Incidence of mucocutaneous reactions in children treated with niflumic acid, other nonsteroidal antiinflammatory drugs, or nonopioid analgesics. *Pediatrics.* 2005;116:26–33. [[PubMed](#)]
- Summary of the National Institutes of Health consensus. 1994. *Helicobacter pylori* in peptic ulcer disease. *Maryland Medical Journal.* 43:923–4.
- Sweetman C., S., 2009. 'Martindale: The Complete Drug Reference 36th Edition'. Pharmaceutical Press. London. United Kingdom.
- Talley NJ, Zinsmeister AR, Schleck CD, Melton LJ 3rd. *Dyspepsia and dyspepsia subgroups: a population-based study. Gastroenterology* 1992; 102 (pt1):1259-1268. A representative sample of 835 adults living in Olmsted County, Minnesota.

- Turner WM. The Food and Drug Administration algorithm. Special workshop—regulatory. *Drug Inf J*. 1984;18:259–66. [PubMed: 10268553]
- Utrecht, Jack. 2010. *Handbook Experimental Pharmacology Adverse Drug Reaction*. Springer. Toronto. Canada
- Vadokas B. et al. 1997. “Effects of gastrin-releasing peptide (GRP) on the mechanical activity of the human ileocaecal region in vitro.” *Journal of Neurogastroenterology & Motility*. 9(4):265–270.
- Van Mil JW, Westerlund LO, Hersberger KE, Schaefer MA (2004) Drug-related problem classification systems. *Ann Pharmacother* 38: 859–867
- Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. *Nature* 1971
- Wachirawat W. et al. 2003. “Stress, but not *Helicobacter pylori*, is associated with peptic ulcer disease in a Thai population.” *Journal of the Medical Association of Thailand*. 86(7):672–85.
- Wallace, J.L., 2000. How do NSAIDs cause ulcer disease? *ResearchGate*, **14**: 147–59.
- Wallace, J.L., 2001. Pathogenesis of NSAID-induced gastroduodenal mucosal injury. *ResearchGate*, **15**: 691–703.
- Whittle BJR. Temporal relationship between cyclooxygenase inhibition, as measured by prostacyclin biosynthesis, and the gastrointestinal damage induced by indomethacin in the rat. *Gastroenterology* 1981; 80: 94-98.
- WHO. The use of the WHO-UMC system for standardized case causality assessment. World Health Organization (WHO) — Uppsala Monitoring Centre. [Last accessed on 2013 Apr 10]. Available from: <http://www.whoumc.org/Graphics/24734.pdf> .
- Wiffen, P., Mitchell, M., Snelling, M. and Stoner, N., 2007, *Oxford Handbook of Clinical Pharmacy*, Oxford University Press Inc., New York United States, 18-22.
- Wilcox CM, Cryer B, Triadafilopoulos G. Patterns of use and public perception of over-the-counter pain relievers: focus on nonsteroidal antiinflammatory drugs. *J Rheumatol*. 2005;32(11):2218–2224
- Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. *N Engl J Med* 1999; 340: 1888-1899
- Zhou Y, Boudreau DM, Freedman AN. Trends in the use of aspirin and nonsteroidal anti-inflammatory drugs in the general U.S. population. *Pharmacoepidemiol Drug Saf*. 2014;23(1):43–50.